bioMérieux reported consolidated sales results for the fourth quarter and year ended December 31, 2016. For the quarter, the company reported total consolidated sales of €591.5 million against €553.1 million a year ago. Organic growth remained solid in fourth-quarter 2016, as sales gained 7.8% on the prior-year period. Continued good sales momentum in the Americas and an upward trend in Europe offset the expected decline in the Asia-Pacific region following its strong fourth-quarter 2015 performance. Asia-Pacific sales were consequently more evenly distributed from quarter to quarter. FilmArray made another strong contribution to growth in fourth-quarter 2016. Business growth was chiefly spurred by sales of reagents and services. For the year, the company reported consolidated sales amounted to €2,103 million in 2016, versus €1,965 million in 2015. Year-on-year organic sales growth (i.e., at constant exchange rates and scope of consolidation) outperformed objectives at 9.6%, led by an acceleration of around 500bp driven by FilmArray sales. In a volatile currency environment, reported sales growth came to 7.1%, held back by a negative currency effect of around €33 million, as well as the change in scope resulting primarily from the deconsolidation of bioTheranostics as of January 1, 2016. At December 31, 2016, net debt amounted to €275 million, including €42 million in debt under the finance lease relating to the extension of the Marcy l’Étoile (France) site after it was delivered in third-quarter 2016 (€219 million at end-2015).